These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 24397325)

  • 1. Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C.
    Keshvari M; Pouryasin A; Behnava B; Sharafi H; Hajarizadeh B; Alavian SM
    Aliment Pharmacol Ther; 2014 Feb; 39(3):343. PubMed ID: 24397325
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C--authors' reply.
    Stättermayer AF; Ferenci P
    Aliment Pharmacol Ther; 2014 Feb; 39(3):344. PubMed ID: 24397327
    [No Abstract]   [Full Text] [Related]  

  • 3. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
    Stättermayer AF; Strassl R; Maieron A; Rutter K; Stauber R; Strasser M; Beinhardt S; Datz C; Scherzer TM; Steindl-Munda P; Gschwantler M; Trauner M; Hofer H; Ferenci P
    Aliment Pharmacol Ther; 2014 Jan; 39(1):104-11. PubMed ID: 24205831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks?
    Galmozzi E; Lampertico P
    Aliment Pharmacol Ther; 2014 Mar; 39(5):548-9. PubMed ID: 24494849
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks? Authors' reply.
    Stättermayer AF; Ferenci P
    Aliment Pharmacol Ther; 2014 Mar; 39(5):549-50. PubMed ID: 24494850
    [No Abstract]   [Full Text] [Related]  

  • 6. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
    Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
    Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C.
    Krämer B; Nischalke HD; Boesecke C; Ingiliz P; Voigt E; Mauss S; Stellbrink HJ; Baumgarten A; Rockstroh JK; Spengler U; Nattermann J
    AIDS; 2013 Nov; 27(17):2817-9. PubMed ID: 23939236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.
    Wiegand SB; Heidrich B; Susser S; Rogalska-Taranta M; Petersen J; Böker KH; Grigorian N; Link R; Naumann U; John C; Lueth S; Malfertheiner P; Manns MP; Wedemeyer H; Sarrazin C; Cornberg M
    PLoS One; 2015; 10(12):e0145622. PubMed ID: 26699619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients.
    Franco S; Aparicio E; Parera M; Clotet B; Tural C; Martinez MA
    AIDS; 2014 Jan; 28(1):133-6. PubMed ID: 24072198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
    Murakawa M; Asahina Y; Kawai-Kitahata F; Nakagawa M; Nitta S; Otani S; Nagata H; Kaneko S; Asano Y; Tsunoda T; Miyoshi M; Itsui Y; Azuma S; Kakinuma S; Tanaka Y; Iijima S; Tsuchiya K; Izumi N; Tohda S; Watanabe M
    J Med Virol; 2017 Jul; 89(7):1241-1247. PubMed ID: 28036111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3.
    Holmes JA; Congiu M; Bonanzinga S; Sandhu MK; Kia YH; Bell SJ; Nguyen T; Iser DM; Visvanathan K; Sievert W; Bowden DS; Desmond PV; Thompson AJ
    Aliment Pharmacol Ther; 2015 Aug; 42(3):296-306. PubMed ID: 26032235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.
    Lindh M; Lagging M; Arnholm B; Eilard A; Nilsson S; Norkrans G; Söderholm J; Wahlberg T; Wejstål R; Westin J; Hellstrand K
    J Viral Hepat; 2011 Jul; 18(7):e325-31. PubMed ID: 21692944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation.
    Fernández-Carrillo C; Coto-Llerena M; González P; Crespo G; Mensa L; Caro-Pérez N; Gambato M; Navasa M; Forns X; Pérez-del-Pulgar S
    J Clin Virol; 2014 Oct; 61(2):282-5. PubMed ID: 25130512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients.
    Riva E; Scagnolari C; Monteleone K; Selvaggi C; Picardi A; Mazzarelli C; Pizzigallo E; Vincenzi B; Carducci A; Antonaci S; Giannelli G; Antonelli G
    J Viral Hepat; 2012 Sep; 19(9):650-3. PubMed ID: 22863269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].
    Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Pálinkás L; Berki T; Vincze A; Kisfali P; Melegh B
    Orv Hetil; 2013 Aug; 154(32):1261-8. PubMed ID: 23916907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6.
    Akkarathamrongsin S; Thong VD; Payungporn S; Poovorawan K; Prapunwattana P; Poovorawan Y; Tangkijvanich P
    J Med Virol; 2014 Sep; 86(9):1482-90. PubMed ID: 24782280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 ΔG allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients.
    Galmozzi E; Aghemo A
    J Clin Virol; 2014 Apr; 59(4):274-5. PubMed ID: 24495847
    [No Abstract]   [Full Text] [Related]  

  • 18. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
    Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
    PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of IL-28B SNPs on control of hepatitis C virus infection: a genome-wide association study.
    Imazeki F; Yokosuka O; Omata M
    Expert Rev Anti Infect Ther; 2010 May; 8(5):497-9. PubMed ID: 20455677
    [No Abstract]   [Full Text] [Related]  

  • 20. Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?
    Veillon P; Fouchard-Hubert I; Larrey D; Dao MT; D'alteroche L; Boyer-Darrigand N; Picard N; Le Guillou-Guillemette H; Saulnier P; Ducancelle A; Loustaud-Ratti V; Lunel-Fabiani F
    J Interferon Cytokine Res; 2016 Mar; 36(3):204-14. PubMed ID: 26700738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.